Financial Performance - IMUNON reported a net loss of $19.5 million for 2023, a decrease from a net loss of $35.9 million in 2022, equating to $2.16 per share compared to $5.03 per share in the previous year[18]. - Total operating expenses for 2023 were $21.0 million, down from $25.4 million in 2022, reflecting a 17.3% reduction[31]. - Cash used for operating activities decreased to $19.0 million in 2023 from $23.1 million in 2022, primarily due to a one-time interest expense of $4.5 million in 2022[22]. - The Company ended 2023 with $15.7 million in cash, investments, and accrued interest receivable, which is expected to fund operations into Q4 2024[23]. - The Company has no licensing revenue in 2023, compared to $500,000 in 2022[31]. - Total assets decreased to $21.9 million in 2023 from $44.0 million in 2022, a decline of 50.2%[33]. Operating Expenses - Operating expenses for 2023 were $21.0 million, down by $4.4 million or 17% from $25.4 million in 2022[18]. - General and administrative expenses decreased to $9.7 million in 2023 from $13.7 million in 2022, primarily due to lower non-cash stock compensation and employee-related costs[20]. - General and administrative expenses decreased to $9.7 million in 2023 from $13.7 million in 2022, a reduction of 29.0%[31]. - CMC costs increased to $2.3 million in 2023 from $1.2 million in 2022 due to the development of in-house pilot manufacturing capabilities[19]. Research and Development - Research and development (R&D) expenses were $11.3 million for 2023, a slight decrease from $11.7 million in 2022, with costs associated with the OVATION 2 Study at $1.2 million[19]. - The Company is advancing its lead clinical program, IMNN-001, for advanced ovarian cancer, currently in Phase 2 development[27]. - The Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab has enrolled four patients, with a total of 50 patients expected to be enrolled[10][11]. - Interim data from the OVATION 2 Study indicated a 30% delay in disease progression or death in the treatment arm compared to the control arm, with an approximate nine-month improvement in overall survival[2]. - IMUNON submitted an Investigational New Drug (IND) application for a Phase 1/2 clinical trial of a seasonal COVID-19 booster vaccine in Q1 2024[2]. - The Company is entering a first-in-human study of its COVID-19 booster vaccine, IMNN-101[27]. - The PlaCCine modality demonstrated robust and durable T cell responses in preclinical studies, outperforming commercial mRNA vaccines in animal models[4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1256615 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1256615 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. NA (Former name, former address and former fiscal year, if changed since last repo ...

COMMISSION FILE NO.: 001-15911 For the fiscal year ended December 31, 2022. or UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 FORM 10-K (Mark One) For the transition period from _______ to _______ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) | Title of each class | Trading Symbol(s) | Name ...

Imunon, Inc. (NASDAQ:IMNN) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Kim Golodetz - Investor Relations Corinne Le Goff - President and Chief Executive Officer Jeffrey Church - Chief Financial Officer Khursheed Anwer - Chief Science Officer Nicholas Borys - Chief Medical Officer Conference Call Participants Emily Bodnar - H.C. Wainwright & Co, LLC James Molloy - Alliance Global Partners David Bautz - Zacks Small-Cap Research Operator Good morning. My name is Marliese ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1256615 (St ...

Celsion Corporation (CLSN) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne Le Goff - President & CEO Jeffrey Church - CFO Nicholas Borys - CMO Khursheed Anwer - Chief Science Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Kumar Raja - Brookline Capital Markets David Bautz - Zacks Small-Cap Research Operator Good morning, and welcome to Celsion's Second Quarter 2022 Earnin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 CELSION CORPORATION (Exact name of Registrant as specified in its charter) Delaware 52-1256615 ( ...

Celsion Corporation (CLSN) Q1 2022 Earnings Conference Call May 16, 2022 11:00 AM ET Company Participants Monique Kosse - Investor Relations Michael Tardugno - Chairman, Chief Executive Officer and President Jeff Church - Chief Financial Officer Nicholas Borys - Chief Medical Officer Khursheed Anwer - Chief Science Officer Conference Call Participants Emily Bodnar - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Good day, everyone and welcome to Celsion’s First Quarter 2022 Earnings Call. M ...